Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

2(33.3%)

6Total

Phase 1(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02082860Phase 1Completed

Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria

Role: lead

NCT02076763Completed

Observational Study of Acute Intermittent Porphyria Patients

Role: lead

NCT01334697Phase 1Unknown

Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Cardiotrophin-1 in Healthy Volunteers

Role: lead

NCT00781053Phase 2Completed

Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study

Role: collaborator

NCT00574613Phase 2Completed

Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis

Role: collaborator

NCT01121731Phase 1Completed

A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C

Role: lead

NCT00656825Phase 1Completed

Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers

Role: collaborator

All 7 trials loaded